Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC.

ABSTRACT:

Background

Oxidative stress associated with severe cardiopulmonary diseases leads to impairment in the nitric oxide/soluble guanylate cyclase signaling pathway, shifting native soluble guanylate cyclase toward heme-free apo-soluble guanylate cyclase. Here we describe a new inhaled soluble guanylate cyclase activator to target apo-soluble guanylate cyclase and outline its therapeutic potential.

Methods

We aimed to generate a novel soluble guanylate cyclase activator, specifically designed for local inhaled application in the lung. We report the discovery and in vitro and in vivo characterization of the soluble guanylate cyclase activator mosliciguat (BAY 1237592).

Results

Mosliciguat specifically activates apo-soluble guanylate cyclase leading to improved cardiopulmona

SUBMITTER: Becker-Pelster EM 

PROVIDER: S-EPMC9526466 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature